Home › NDC Lookup › RxCUI directory › RxCUI 2394941

Pralsetinib 100 MG Oral Capsule — RxCUI 2394941

RxNorm drug concept · Semantic clinical drug
RxCUI 2394941 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2394941
Official namePralsetinib 100 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped6
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pralsetinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Gavreto only works against cancers that have a specific genetic change called a RET gene fusion. Without that change, the drug has no target to block. Your doctor uses an FDA-appro...
  • Why does my tumor need to be tested before I can start this medication?
  • Yes, it matters a lot. You need to take Gavreto on a completely empty stomach — that means no food for at least 2 hours before and at least 1 hour after your dose. Studies showed t...
  • Does it matter if I eat before taking my capsule?
📖 Read our full Pralsetinib guide →

🕸️ Concept Web — How Pralsetinib 100 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Pralsetinib 100 MG Oral Capsule RxCUI 2394941

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Pralsetinib 2394936
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Gavreto 2394942
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Pralsetinib Oral Capsule 2394940
    • Pralsetinib Oral Product 2394938
    • Pralsetinib Pill 2394939
    • Pralsetinib Oral Capsule [Gavreto] 2394944
    • Gavreto Oral Product 2394945
    • Gavreto Pill 2394946
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Pralsetinib 100 MG SCDC · 2394937
  • Pralsetinib Oral Capsule SCDF · 2394940
  • Pralsetinib Oral Product SCDG · 2394938
  • Pralsetinib Pill SCDG · 2394939

Brand-Name Concepts

  • Pralsetinib 100 MG Oral Capsule [Gavreto] SBD · 2394947
  • Pralsetinib 100 MG [Gavreto] SBDC · 2394943
  • Pralsetinib Oral Capsule [Gavreto] SBDF · 2394944
  • Gavreto Oral Product SBDG · 2394945
  • Gavreto Pill SBDG · 2394946
  • Gavreto BN · 2394942

📦 FDA Products & Package NDCs

2 products · 6 package NDCs
6 package NDCs map to RxCUI 2394941 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50242-0210-60 1 BOTTLE in 1 CARTON (50242-210-60) / 60 CAPSULE in 1 BOTTL... Gavreto Genentech, Inc. 2021-07-01
50242-0210-83 1 BOTTLE in 1 CARTON (50242-210-83) / 60 CAPSULE in 1 BOTTL... Gavreto Genentech, Inc. 2021-07-01
50242-0210-90 1 BOTTLE in 1 CARTON (50242-210-90) / 90 CAPSULE in 1 BOTTL... Gavreto Genentech, Inc. 2021-07-01
71332-0006-12 120 CAPSULE in 1 BOTTLE (71332-006-12) Gavreto Rigel Pharmaceuticals, Inc. 2024-06-24
71332-0006-60 60 CAPSULE in 1 BOTTLE (71332-006-60) Gavreto Rigel Pharmaceuticals, Inc. 2024-06-24
71332-0006-90 90 CAPSULE in 1 BOTTLE (71332-006-90) Gavreto Rigel Pharmaceuticals, Inc. 2024-06-24
Observed labelers: Genentech, Inc. (3) · Rigel Pharmaceuticals, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.